Table 3.
Comparison of immunogenicity between steroid-treated and nontreated groups of young children with recurrent wheezing
| Influenza strain and immunogenicity endpointa | Steroid-treated group (N = 33) | Non-steroid-treated group (N = 29) | P |
|---|---|---|---|
| A/California(H1N1) | |||
| Seroconversion (n [% (95% CI)]) | 23 (69.70 [54.02–85.38]) | 18 (62.07 [44.31–79.73]) | 0.5266 |
| Seroprotection (n [% (95% CI)]), day 28 | 25 (75.76 [61.14–90.38]) | 21 (72.41 [56.15–88.68]) | 0.7640 |
| GMT (95% CI), day 0 | 6.29 (3.02–12.24) | 5.53 (2.50–11.18) | 0.4870 |
| GMT (95% CI), day 28 | 56.67 (33.05–96.67) | 56.04 (32.88–95.05) | 0.4430 |
| GMTR | 6.91 | 7.74 | 0.3901 |
| A/Perth(H3N2) | |||
| Seroconversion (n [% (95% CI)]) | 26 (78.99 [64.84–92.74]) | 20 (68.97 [52.13–85.80]) | 0.3378 |
| Seroprotection (n [% (95% CI)]), day 28 | 26 (78.79 [64.84–92.74]) | 22 (75.86 [60.29–91.44]) | 0.7834 |
| GMT (95% CI), day 0 | 1.70 (0.65–3.41) | 2.27 (0.75–5.11) | 0.5455 |
| GMT (95% CI), day 28 | 54.87 (34.51–86.91) | 63.71 (38.96–103.79) | <0.0001 |
| GMTR | 19.72 | 18.81 | 0.4671 |
| B/Brisbane | |||
| Seroconversion (n [% (95% CI)]) | 18 (54.55 [37.56–71.53]) | 20 (68.97 [52.13–85.80]) | 0.2448 |
| Seroprotection (n [% (95% CI)]), day 28 | 21 (63.64 [47.72–80.05]) | 23 (79.31 [64.57–94.05]) | 0.1749 |
| GMT (95% CI), day 0 | 7.69 (4.75–12.12) | 11.04 (7.19–16.70) | <0.0001 |
| GMT (95% CI), day 28 | 37.85 (28.88–49.50) | 51.89 (37.77–71.15) | <0.0001 |
| GMTR | 3.47 | 3.39 | 0.8766 |
a
Seroconversion was defined as a prevaccination antibody titer of ≤1:10 and a postvaccination titer of ≥1:40. Seroprotection was defined as a postvaccination antibody titer of ≥1:40. CI, confidence interval; GMTR, geometric mean of post- to prevaccination titer ratios; GMT, geometric mean titer.